The 2026 Spring to Life conference, hosted by New York Oncology Hematology (NYOH), will spotlight the evolving landscape of plasma cell disorders, with a focus on translating emerging evidence into clinical practice. Designed for a diverse, interprofessional healthcare audience, this year’s program will explore the continuum from premalignant conditions (MGUS, MGRS, smoldering myeloma) to advanced disease states, while addressing both malignant and benign hematology.
Participants will gain insight into current and novel therapeutic approaches, including CAR-T therapy, bispecific antibodies, and next-generation sequencing (NGS) for minimal residual disease (MRD) assessment. The conference will also feature rare plasma cell disorders such as AL amyloidosis, Castleman disease, and POEMS syndrome, as well as targeted discussions on underserved conditions like sickle cell disease.
A keynote session will explore the future of myeloma care, including the potential for functional cures and treatment-free intervals. Through evidence-based updates, case discussions, and interdisciplinary dialogue, this event will foster collaboration to advance patient outcomes across hemtalogic care settings.
